Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Gregersen
Colin Gregersen, Salt Lake City, UT US
| Patent application number | Description | Published |
|---|---|---|
| 20110040339 | SURGICAL SCREW AND METHOD OF PERFORMING LIGAMENT RECONSTRUCTION USING SAID SCREW - This invention relates to a system and a method for affixing soft tissue to bones. The system for fixing soft tissue within a bone tunnel comprising a first fixation member having a proximal end and a distal end and a bore extending from said proximal end to said distal end, said first fixation member is adapted for insertion against a first portion of a soft tissue positioned within a bone tunnel, a second portion of said soft tissue emerging from said bone tunnel; a second fixation member adapted to engage said bore of said first fixation member, having means for restraining disengagement therewith and a proximal end; and a third fixation member adapted to engage said second portion of said soft tissue, having means for coupling onto said proximal end of said second fixation member and restraining disengagement therewith. | 02-17-2011 |
Colin S. Gregersen, Salt Lake City, UT US
| Patent application number | Description | Published |
|---|---|---|
| 20090112153 | SPLIT-TIP CATHETER INCLUDING LATERAL DISTAL OPENINGS - A split-tip catheter for placement within the vasculature of a patient and for use in hemodialysis or other suitable procedures is disclosed. In one embodiment, the split-tip catheter includes a catheter body that defines a first lumen and a second lumen. The catheter body further comprises a split distal region, including a venous segment that defines a distal portion of the first lumen and an arterial segment that defines a distal portion of the second lumen. The venous segment includes a recess extending proximally of a nose portion; and a lateral opening in fluid communication with the first lumen. The arterial segment is separate from the venous segment and is removably seatable in the recess provided by the venous segment such that it “nests” therein. The arterial segment also includes a lateral opening in fluid communication with the second lumen. | 04-30-2009 |
| 20090192435 | SOLID-BODY CATHETER INCLUDING LATERAL DISTAL OPENINGS - A split-tip catheter for placement within the vasculature of a patient and for use in hemodialysis or other suitable procedures is disclosed. In one embodiment, the split-tip catheter includes a catheter body that defines a first lumen and a second lumen. The catheter body further comprises a split distal region, including a venous segment and an arterial segment. The venous segment includes a recess extending proximally of a nose portion; and a lateral opening in fluid communication with the first lumen. The arterial segment also includes a lateral opening, is separate from the venous segment, and is removably seatable in the recess provided by the venous segment. In one embodiment, the distal region is un-split, but includes symmetrically opposed lateral openings, as well as distal openings, in communication with the first and second lumens for providing a functional stagger for blood flow in both forward and reverse catheter flow directions. | 07-30-2009 |
Jens-Peter Gregersen, Wetter DE
| Patent application number | Description | Published |
|---|---|---|
| 20100183671 | LOW-ADDITIVE INFLUENZA VACCINES - An influenza vaccine that lacks at least three of a mercurial preservative; an antibiotic; formaldehyde; and egg-derived materials. In some embodiments, the vaccine includes none of these four components. | 07-22-2010 |
Jens-Peter Gregersen, Marburg DE
| Patent application number | Description | Published |
|---|---|---|
| 20090081252 | DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES - Influenza viruses for use in preparing human vaccines have traditionally been grown on embryonated hen eggs, although more modern techniques grow the virus in mammalian cell culture e.g. on Vero, MDCK or PER.C6 cell lines. The inventor has realised that the conditions used for influenza virus 5 culture can increase the risk that pathogens other than influenza virus may grow in the cell lines and have identified specific contamination risks. Suitable tests can thus be performed during manufacture in order to ensure safety and avoid iatrogenic infections. | 03-26-2009 |
| 20090304729 | CELL-DERIVED VIRAL VACCINES WITH LOW LEVELS OF RESIDUAL CELL DNA - The present invention relates to vaccine products for the treatment or prevention of viral infections. Further provided are methods of reducing contaminants associated with the preparation of cell culture vaccines. Residual functional cell culture DNA is degraded by treatment with a DNA alkylating agent, such as β-propiolactone (BPL), thereby providing a vaccine comprising immunogenic proteins derived from a virus propagated on cell culture, substantially free of residual functional cell culture DNA. | 12-10-2009 |
Michael Gregersen, Warren, MI US
| Patent application number | Description | Published |
|---|---|---|
| 20090266325 | MICROWAVE COMBUSTION SYSTEM FOR INTERNAL COMBUSTION ENGINES - A microwave combustion system is presented that can replace the conventional spark plug in an internal combustion engine. One or more microwave pulses are provided to a microwave feed in a plug that sits in the cylinder. A microwave generated plasma generated by the plug in the vicinity of a fuel mixture can provide for highly efficient combustion of the fuel-air mixture. | 10-29-2009 |
Peter K. Gregersen, Larchmont, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20100303813 | BIOMARKERS FOR PREDICTING ANTI-TNF RESPONSIVENESS OR NON-RESPONSIVENESS - The present disclosure provides biomarkers that are predictive a subject's responsiveness or non-responsiveness to an anti-TNF therapy. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities (e.g., an anti-TNF therapy or a non-anti-TNF therapy) for a subject suffering from a disease such as an immune disorder. | 12-02-2010 |
| 20110027822 | SYSTEMIC LUPUS ERYTHEMATOSUS - This document relates to methods and materials involved in diagnosing SLE. For example, this document relates to methods and materials involved in diagnosing SLE, diagnosing severe SLE, and assessing a mammal's susceptibility to develop severe SLE. For example, this document provides nucleic acid arrays that can be used to diagnose SLE in a mammal. Such arrays can allow clinicians to diagnose SLE based on a simultaneous determination of the expression levels of many genes that are differentially expressed in SLE patients as compared to healthy controls. In addition, methods and materials for assessing SLE activity, determining the likelihood of experiencing active SLE, and detecting SLE treatment effectiveness are provided herein. | 02-03-2011 |